William Blair Investment Management LLC Invests $12.25 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

William Blair Investment Management LLC acquired a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 506,706 shares of the company’s stock, valued at approximately $12,252,000. William Blair Investment Management LLC owned about 0.23% of Hims & Hers Health as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter worth $28,000. Raleigh Capital Management Inc. increased its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. increased its holdings in Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC increased its holdings in Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock valued at $36,000 after purchasing an additional 1,413 shares in the last quarter. Finally, US Bancorp DE increased its holdings in Hims & Hers Health by 346.7% in the 4th quarter. US Bancorp DE now owns 1,943 shares of the company’s stock valued at $47,000 after purchasing an additional 1,508 shares in the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Hims & Hers Health

In related news, CEO Andrew Dudum sold 128,127 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $33.98, for a total transaction of $4,353,755.46. Following the completion of the sale, the chief executive officer now owns 173,655 shares of the company’s stock, valued at $5,900,796.90. This represents a 42.46 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Oluyemi Okupe sold 4,213 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $29.98, for a total transaction of $126,305.74. Following the completion of the transaction, the chief financial officer now directly owns 128,365 shares in the company, valued at $3,848,382.70. This represents a 3.18 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,034,506 shares of company stock worth $36,635,024 over the last 90 days. Insiders own 17.71% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on HIMS shares. Bank of America increased their target price on Hims & Hers Health from $21.00 to $22.00 and gave the company an “underperform” rating in a research note on Tuesday. Canaccord Genuity Group increased their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research report on Wednesday, February 19th. BTIG Research assumed coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price objective for the company. Citigroup reaffirmed a “sell” rating and set a $27.00 price target on shares of Hims & Hers Health in a report on Thursday, March 6th. Finally, Piper Sandler raised their price target on shares of Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, February 25th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $37.31.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $33.85 on Thursday. The stock has a 50-day simple moving average of $38.88 and a 200 day simple moving average of $28.52. Hims & Hers Health, Inc. has a one year low of $11.20 and a one year high of $72.98. The company has a market capitalization of $7.52 billion, a price-to-earnings ratio of 76.94 and a beta of 1.37.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, February 24th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of $0.09 by $0.02. The company had revenue of $481.14 million during the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.